1 May 2026

AOTI, INC. (the "Company" or "Group" or "AOTI")

Employee Share Purchase Plan

AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering outcomes-based care at home, by more durable healing of wounds and the prevention of amputations, announces the establishment of an Employee Share Purchase Plan (ESPP). CSC Global¹ is acting as administrator of and trustee to, the ESPP.

The principal terms of the plan are as follows:

i.    Eligible employees elect to contribute for twelve months up to a maximum monthly value of either GBP 300, USD 400 or EUR 350, which is deducted from after tax pay and used to purchase Investment Shares.

ii.    Existing common shares ("Investment Shares") are acquired by the trustee quarterly at the prevailing market price on behalf of participating employees.

iii.   One new common share ("Matching Share") will be awarded to employees at nil cost for every four Investment Shares purchased.

iv.   There is a three-year vesting period from the commencement of the ESPP to qualify for Matching Shares.

v.    Matching Shares will be forfeited under certain conditions such as if an employee leaves AOTI or sells the Investment Shares before the end of the vesting period.

On 30 April 2026, the following PDMRs of the Company enrolled in the ESPP and have committed to monthly contributions for twelve months as per the table below:

¹CSC Global operates through CSC Employee Benefit Trustee (Jersey) Limited and CSC Employee Benefit Services (Jersey) Limited

 For more information:

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO₂^®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO₂^® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO₂^® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO₂^® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net

END